Furthermore the specific role of these lipid subclasses on

Furthermore, the specific role of these lipid subclasses on immune EHT 1864 is uncertain, and may vary according to lipid subtypes. Evidence suggests that depending on the subtype, some phosphatidylethanolamines have a pro-inflammatory role in activating macrophages (Guo et al., 2015), and appear to be elevated in several cancers (Perrotti et al., 2016). We also observed that sCD163 was positively correlated with the phosphatidylethanolamine and triacylglycerol classes, but inversely with the GM3 ganglioside class correlated inversely with sCD163. GM3 gangliosides can have both pro-inflammatory and anti-inflammatory effects (Wentworth et al., 2016; Kim et al., 2014), similar to expression of CD163. The precise link between lipids like phosphatidylethanolamine and monocyte immune activation has not been established. However, phosphatidylethanolamine is a ligand for the phospholipid receptor CD300a that belongs to the CD300 family of paired activating/inhibitory receptors that are highly expressed on myeloid cells including monocytes (Carnec et al., 2015). Pro-inflammatory intermediate and non-classical monocytes have high cell surface levels of CD300a than classical monocytes (Zenarruzabeitia et al., 2016). Furthermore, like Glut1, CD300a is a LPS-responsive hypoxia-inducible gene, regulated by hypoxic environments to induce monocyte/macrophage activation and pro-inflammatory responses (Raggi et al., 2014). Since CD300a may be regulated by PI3Kinase, which also regulates Glut1 and glycolysis, further investigation is warranted to determine if CD300a centrally connects inflammatory lipids, with immune cellular glucose metabolism and inflammatory-mediated responses, and if this is central to frailty pathogenesis. Adoption of a pro-inflammatory monocyte state in diseases has generally centered on the relationship with plasma levels of inflammatory cytokines such as TNF-α, IL-6 and IL-1β. Less is known about the direct impact of perturbed plasma lipid profiles on immune cell metabolism, and how this interaction influences innate and adaptive immune activation, and the course of diseases. Further work is warranted to establish such associations.
Funding Sources This group received a grant from Merck Sharp & Dohme for the materials of this study. The funding sources had no role in designing the study, in collecting, analyzing, interpreting or reporting the data, or in deciding to submit the article for publication. C.S.P. is a recipient of the Australian Centre for HIV and Hepatitis Virology Research () grant, and a 2010 developmental grant (CNIHR) from the University of Washington Center for AIDS Research (CFAR), an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA). Some assays employed in this study were developed under these funding schemes. There was no other funding source for this study.
Introduction Neutralizing antibodies (NAbs) are a good correlate of protection in infectious diseases such as yellow fever, smallpox, and measles (Amanna et al., 2008). The potential protective role of Nabs during the course of human immunodeficiency virus (HIV) infection remains a highly debated issue. Many HIV-infected individuals naturally develop NAbs that target several sites on the gp41 and gp120 HIV-1 envelope proteins after several years of infection, but only 10–25% develop potent and broadly reactive Nabs (Mikell et al., 2011; Hraber et al., 2014; West et al., 2014). These findings suggest that the human immune system can achieve NAb responses, but whether these Abs are naturally protective during HIV infection remains unclear. Studies of NAbs in general have provided an enormous impetus to HIV vaccine research and to immunology as a whole (Sadanand et al., 2016). Monoclonal Abs (mAbs) with the remarkable ability to neutralize most circulating strains of HIV-1 were recently isolated from HIV-infected individuals. Examples include 3BNC117 and PGT121 mAbs, which both transiently block infection and suppress viremia in simian/HIV (SHIV)-infected macaques, demonstrating that the passive administration of potent NAbs protects macaques for a short period of time (Barouch et al., 2013). In HIV-1-infected humans, a single infusion of 3BNC117 mAb, which specifically targets the CD4-binding site on gp120, decreased viremia for up to 28days (Caskey et al., 2015).